The US vaccines specialist Moderna, which made its name through the success of its Covid-19 shot, is preparing to launch a new respiratory shot, putting it in competition with GSK.
Moderna said it continued to expect initial regulatory approvals for its respiratory syncytial virus (RSV) vaccine for older adults from the first half of this year.
The Massachusetts-based company became one of the first with a vaccine to combat Covid-19 and said on Thursday that it “is well-prepared for the launch of its second respiratory vaccine, which will build upon the success of its commercial efforts in the Covid-19 market”.
Its profits and share price soared in New York during the height of the pandemic but both have dropped as the crisis waned, and its
